Veozah (Fezolinetant) Explained: The Non-Hormonal Hot Flash Drug

If you have been searching for a way to calm hot flashes but cannot take hormones, or simply prefer not to, a relatively new prescription medication called Veozah may be worth a serious conversation with your doctor. Veozah is the brand name for fezolinetant, and it is the first drug in a brand-new class of non-hormonal treatments designed specifically to target the brain circuit that triggers hot flashes in the first place. The FDA approved Veozah (fezolinetant) on May 12, 2023, calling it a novel drug to treat moderate to severe hot flashes caused by menopause. That approval was a meaningful moment for the millions of women who either cannot safely use estrogen or who have tried hormonal options and want something different.

This article will walk you through exactly what fezolinetant is, the science behind how it works, what the clinical trial results actually showed, who is the best candidate for it, what side effects and warnings you need to know about, and how it compares to other treatments. Hot flashes are not just uncomfortable. For many women they disrupt sleep, concentration, work, and relationships. Understanding every tool available to you matters. If you want to start by checking your symptoms, the FindMyHRT symptom quiz is a good first step.

Why Hot Flashes Happen: The Brain Chemistry Behind the Burn

To understand why fezolinetant works, you first need to understand why hot flashes happen at all. During the reproductive years, estrogen quietly keeps a group of specialized neurons in the hypothalamus in check. These neurons, called KNDy neurons (named for the chemicals they produce: kisspeptin, neurokinin B, and dynorphin), play a key role in regulating body temperature. Estrogen suppresses the activity of a signaling molecule called neurokinin B (NKB), which these neurons release. When estrogen levels fall during perimenopause and menopause, that natural brake is gone.

Without estrogen's calming influence, neurokinin B surges. It activates a receptor called the neurokinin 3 (NK3) receptor, which sits in the brain's temperature-control center. When that receptor fires repeatedly, it essentially tricks the hypothalamus into thinking the body is overheating. The body responds the way it always does to overheating: it dilates blood vessels near the skin and triggers sweating to release heat. That is a hot flash. It is not random. It is a predictable chain reaction in the brain, and now there is a drug that interrupts it.

Fezolinetant is what is known as a neurokinin 3 receptor antagonist. In plain language, it binds to the NK3 receptor and blocks neurokinin B from activating it. With that receptor quieted, the false overheating signal is never sent, and the hot flash does not happen, or happens far less often and with less intensity. Because it acts on a specific brain receptor rather than on hormones, fezolinetant does not contain or mimic estrogen, progesterone, or any other hormone. That is the core reason it opens a door for women who have been told hormonal therapy is off the table. If you want to learn more about how hot flashes affect the body or read about night sweats, those pages go deeper on the symptom side.

What the Clinical Trials Actually Showed

The FDA's approval of Veozah was built on results from the BRIGHT SKY clinical program, which included three Phase 3 trials: SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4. Together they enrolled more than 3,000 women across the United States, Canada, and Europe. The pivotal results from SKYLIGHT 1 and SKYLIGHT 2 were published in The Lancet, one of the most respected medical journals in the world.

Here is what the numbers showed:

• In SKYLIGHT 1, at 12 weeks, 57% of women taking the 45 mg dose of fezolinetant had their hot flash frequency cut in half, compared with 30% of women taking a placebo.
• In SKYLIGHT 2, that number was even higher: 61% of women on the 45 mg dose achieved that same 50% reduction in frequency, versus 43% on placebo.
• Reductions in both frequency and severity were statistically significant as early as week 4 of treatment.
• Women taking fezolinetant experienced roughly 60% fewer hot flashes within 12 weeks of starting treatment.

The The Menopause Society (formerly the North American Menopause Society) reviewed this data as part of its 2023 nonhormone therapy position statement and classified fezolinetant as a Level I treatment option, the highest evidence rating, meaning the recommendation is backed by good and consistent scientific evidence. The Society noted that fezolinetant 45 mg reduced vasomotor symptom frequency significantly more than other non-hormonal options including paroxetine, gabapentin, and desvenlafaxine. That is a notable finding because those other medications have been used off-label for years, so having a dedicated non-hormonal drug that outperforms them in head-to-head comparisons represents genuine progress.

Dosage and How to Take It

The approved dose of Veozah is straightforward: 45 mg taken by mouth once a day. You can take it with or without food. There is no titration schedule or complicated ramp-up period. Because the drug works on a brain receptor rather than on hormone levels, you do not have the same kind of timing considerations you might have with transdermal patches or cyclical hormonal therapy. Many women in the clinical trials noticed a difference within the first week. By four weeks, statistically meaningful reductions in both frequency and severity were established.

Fezolinetant is metabolized by an enzyme called CYP1A2 in the liver. That is important because certain medications that strongly inhibit CYP1A2 can raise fezolinetant levels in the blood to unsafe ranges. The FDA specifically contraindicates fezolinetant with three drugs: cimetidine (the heartburn medication sold as Tagamet), fluvoxamine (an antidepressant sold as Luvox), and mexiletine (a heart rhythm medication). If you take any of these, fezolinetant is not an option for you. Make sure your prescriber has a complete list of everything you take, including supplements.

Who Is a Good Candidate for Veozah?

Fezolinetant was designed for women experiencing moderate to severe hot flashes related to menopause. The key populations who may benefit most include:

• Women with a history of hormone-sensitive cancers, particularly breast cancer survivors, who are contraindicated from estrogen-based therapies. Fezolinetant contains no estrogen and does not stimulate estrogen receptors.
• Women with blood clot history (deep vein thrombosis, pulmonary embolism) or other cardiovascular risks that make oral estrogen less advisable.
• Women who tried HRT and stopped due to side effects or personal discomfort with hormonal treatment.
• Women who simply prefer a non-hormonal approach and want a treatment designed specifically for hot flashes, not repurposed from another condition.

It is not the right fit for everyone. Women with pre-existing liver disease, including cirrhosis, should not take fezolinetant. And women who are pregnant or breastfeeding are also excluded. This is a treatment for the menopause transition, not for any other phase of reproductive life. You can explore the full range of non-hormonal treatment options on FindMyHRT if you want to see how fezolinetant fits into the broader landscape.

How Does Veozah Compare to Hormone Therapy?

This is one of the most common questions women ask, and the honest answer is that hormone therapy is still generally considered more effective at reducing hot flashes overall. Hormone therapy can reduce vasomotor symptoms by up to 90% in many women, while fezolinetant achieved roughly 60% reduction in the clinical trials. That gap matters.

However, the comparison is not always apples to apples. A 2024 systematic review and network meta-analysis published in the journal Menopause found that fezolinetant's effect on vasomotor symptom frequency was not statistically significantly different from hormone therapy regimens in the network analysis, meaning the real-world gap may be smaller than the raw percentages suggest. More importantly, for women who cannot use hormones at all, a 60% reduction in hot flash frequency is a substantial and meaningful improvement in quality of life, not a consolation prize.

If you are weighing your options and want to understand the hormone side of the equation more deeply, the FindMyHRT guides on HRT patches, oral HRT, and comparing HRT types are good starting points. The treatment comparison tool can also help you map your priorities to your options.

Side Effects and the Liver Safety Warning You Need to Know

Every honest conversation about Veozah has to include a clear-eyed look at its safety profile, and specifically the significant update that came after its initial approval.

In the clinical trials, fezolinetant was generally well tolerated. The most commonly reported side effects included abdominal pain, diarrhea, insomnia, back pain, headache, and fatigue. These were mostly mild to moderate and did not cause most trial participants to stop the drug.

However, on September 12, 2024, the FDA added a boxed warning (the most serious type of warning the agency issues) to Veozah's label after postmarketing reports of serious, rare drug-induced liver injury. The warning was prompted by a case in which a patient developed acute mixed hepatocellular and cholestatic liver injury within approximately 40 days of starting fezolinetant. She experienced fatigue, nausea, itching, jaundice, pale stools, and dark urine, along with significantly elevated liver enzyme levels. After stopping the drug, her liver function gradually returned to normal.

Because of this, the monitoring requirements for Veozah are now more rigorous than at launch. Before starting fezolinetant, your provider must order baseline liver function tests, including ALT, AST, alkaline phosphatase, and total and direct bilirubin. Follow-up liver testing is now required monthly for the first three months, then at six months and nine months after starting. That is a meaningful commitment, but it is also a reasonable precaution for catching any problem early, before it becomes serious.

The FDA is clear that patients should stop taking Veozah immediately and seek medical attention if they develop any of the following: new or unusual fatigue, loss of appetite, nausea, vomiting, itching, yellowing of the skin or eyes (jaundice), light-colored stools, or dark urine. Do not wait to see if it passes. Call your provider right away.

Women with existing liver conditions, including cirrhosis, should not take fezolinetant at all. This drug requires a healthy liver to metabolize safely.

Cost, Insurance, and Savings Programs

Cost is a real barrier for many women. Without insurance, Veozah runs approximately $778 for a 30-day supply at major pharmacies, which translates to roughly $9,300 per year. That is a significant expense.

The good news is that insurance coverage has expanded considerably since launch. As of late 2025, approximately 88% of commercial insurance plans covered Veozah. Medicare coverage exists as well, though it varies by plan. If you have commercial insurance, it is worth checking your formulary directly or asking your pharmacist to run a coverage check before assuming you will pay full price.

The manufacturer, Astellas Pharma, offers a savings card program for eligible patients. The program provides the first month at no cost and can reduce ongoing monthly costs to as low as $30 per month for qualified patients. There are no income requirements to participate, and the program covers up to $4,000 in copay assistance per calendar year. Your prescribing provider's office or the Veozah official website can help you access this program at the time of your first prescription.

Questions to Ask Your Provider

If you are curious about fezolinetant, coming to your appointment prepared makes the conversation more productive. A few questions worth raising:

• Are my hot flashes frequent or severe enough that a prescription treatment makes sense, or should I try other options first?
• Do I have any liver conditions or take any medications that would make fezolinetant unsafe for me?
• Will my insurance cover Veozah, and can your office help me access the manufacturer savings card?
• How will we monitor my liver function, and what symptoms should prompt me to call you immediately?
• How does this option compare to hormonal therapy given my personal health history?

The appointment prep tool on FindMyHRT can help you organize these questions before your visit. If you are still figuring out whether you are in perimenopause or menopause at all, the guide on whether you are in perimenopause is a useful read, and questions to ask your HRT doctor covers the broader conversation you should be having.

The Bottom Line on Veozah Fezolinetant

Fezolinetant (Veozah) is a genuinely novel medication. It is not a hormone, it is not an antidepressant being used off-label, and it is not a supplement with shaky evidence behind it. It is the first drug specifically designed to interrupt the brain pathway responsible for menopausal hot flashes, and both the FDA and The Menopause Society have reviewed the evidence and endorsed its use for moderate to severe vasomotor symptoms.

At the same time, it is not for everyone. The boxed liver warning is serious and requires ongoing monitoring. It costs nearly $800 a month without insurance. And for women who can safely use hormonal therapy, HRT still has a longer track record and additional benefits beyond hot flash reduction, including bone protection and cardiovascular effects. The question of which treatment is right for you is exactly the kind of individualized decision that requires a provider who knows your history, your risk factors, and your priorities.

The good news is that options are expanding. For the first time, women who have been told there is nothing they can do about hot flashes if hormones are off the table now have a dedicated, evidence-backed, non-hormonal prescription option to consider. That is worth knowing about.

If you are ready to talk to a provider about fezolinetant or any other menopause treatment, the FindMyHRT telehealth provider directory can connect you with clinicians who specialize in menopause medicine and can evaluate whether Veozah is appropriate for your specific situation.

"For the first time, women who cannot use hormones have a prescription option that was built from the ground up to target the exact brain pathway that causes hot flashes. That is a meaningful shift in what we can offer."

Medical Disclaimer: This article is for general educational purposes only and is not medical advice. Hormone therapy and menopause treatment decisions are individual and should be made with a qualified healthcare provider who knows your full history. Always consult your provider before starting or changing any treatment.